Claims

1. A therapeutic fusion protein for enhancing efferocytosis comprising an integrin binding domain, a phosphatidylserine (PS) binding domain and a solubilizing domain, wherein the solubilizing domain is inserted between the integrin binding domain and the PS binding domain, and wherein the PS binding domain is, a C1 domain and does not comprise a C2 domain,

and wherein the solubilizing domain is HSA or HSA D3.

2. The fusion protein of claim 1, wherein the integrin binding domain comprises a Arginine-Glycine-Aspartic acid (RGD) motif.

3. The fusion protein of any one of the preceding claims, wherein the solubilizing domain is linked directly to the integrin binding domain, to the PS binding domain or to both domains.

4. The fusion protein of any one of the preceding claims, wherein the solubilizing domain is linked indirectly to the integrin binding domain and/or the PS binding domain by a linker.

5. The fusion protein of any one of the preceding claims wherein the solubilizing domain comprises human serum albumin (HSA).

6. A therapeutic fusion protein for enhancing efferocytosis comprising an integrin binding domain, a phosphatidylserine (PS) binding domain and a solubilizing domain, wherein the fusion protein has an amino acid sequence selected from:

- SEQ ID NO: 34,
- SEQ ID NO: 36,
- SEQ ID NO: 73,
- SEQ ID NO: 119,
- SEQ ID NO: 121,
- SEQ ID NO: 125,
- SEQ ID NO: 129,
- SEQ ID NO: 131,
- SEQ ID NO: 133,
- SEQ ID NO: 135,
- SEQ ID NO: 137, or
- SEQ ID NO: 147.

7. Use of the fusion protein of any one of preceding claims in the manufacture of a

medicament for the treatment or prevention of an inflammatory disorder or inflammatory organ injury in an individual in need thereof, wherein the inflammatory disorder or inflammatory organ injury is acute kidney injury, acute respiratory distress syndrome, acute liver injury, sepsis, myocardial infarction, stroke, burns, traumatic injury and inflammatory and organ injuries resulting from ischemia/reperfusion.

8. Use of the fusion protein of any one of claims 1-6 in the manufacture of a medicament for the treatment or, prevention, or amelioration of inhibiting or slowing blood coagulation, microbiome treatment, Inflammatory bowel disease (IBD), fatty acid uptake and/or decreasing gastric motility, microthrombi-dependent disorders, atherosclerosis, cardiac remodeling, tissue fibrosis, acute liver injury, chronic liver diseases, non-alcoholic steatohepatitis (NASH), vascular diseases, age-related vascular disorders, intestinal diseases, sepsis, bone disorders, cancer, Thalassemia, pancreatitis, hepatitis, endocarditis, pneumonia, acute lung injury, osteoarthritis, periodontitis, tissue trauma-induced inflammation, colitis, diabetes, hemorrhagic shock, transplant rejection, radiation-induced damage, splenomegaly, sepsis-induced AKI or multi-organ failure, acute burns, adult and pediatric respiratory distress syndrome, wound healing, tendon repair and neurological diseases

9. The use according to claim 7 or claim 8, wherein the fusion protein is to be administered in combination with another therapeutic agent, wherein the therapeutic agent is an immunosuppressive agent, an immunomodulating agent, an anti-inflammatory agent, an anti-oxidant, an anti-infective agent, a cytotoxic agent or an anti-cancer agent.

10. The fusion protein of any one of claims 1-6 for use in therapy.